NetworkNewsBreaks

FridayJul 07, 2017 12:33 pm

NetworkNewsBreaks – Fifth Street Asset Management, Inc. (NASDAQ: FSAM) to Sell Middle Market CLO Business to NewStar Financial, Inc. (NASDAQ: NEWS)

Fifth Street Asset Management (NASDAQ: FSAM) has agreed to sell Fifth Street CLO Management LLC (FSCM), a wholly owned subsidiary of Fifth Street Holdings L.P., to NewStar Financial (NASDAQ: NEWS). The estimated purchase price is approximately $16 million, net of $13 million of assumed indebtedness, and will be subject to adjustment based on certain working capital items upon closing. The company said it intends to use the proceeds from the transaction toward paying down its credit facility and general corporate purposes. The transaction is expected to close in the third quarter. “We believe that exiting this business line is in…

Continue Reading

FridayJul 07, 2017 12:30 pm

NetworkNewsBreaks – ITUS Corp. (NASDAQ: ITUS) Reports Changes in Management, Names New CEO

ITUS (NASDAQ: ITUS) this morning said that its board of directors has appointed Dr. Amit Kumar as its new president and chief executive officer. Dr. Kumar replaces Robert Berman, who has resigned as president, CEO and as a director. Dr. Kumar joined the company in 2012 as a director, and has served as the company's executive chairman for the past year as well. Additionally, Mike Catelani, ITUS' CFO, has been promoted to chief operating officer. "We've been building a solid scientific foundation through the development of our cancer detection technology, and I look forward to helping the company advance that…

Continue Reading

FridayJul 07, 2017 12:28 pm

NetworkNewsBreaks – Digital Ally, Inc. (NASDAQ: DGLY) Shares Surge on U.S. Patent Office Denying Axon’s (NASDAQ: AAXN) Petition for IPR

Digital Ally (NASDAQ: DGLY) shares jumped 35% this morning after the company reported an important victory in its legal battles against Axon Enterprise, Inc. (NASDAQ: AAXN). The US Patent Office has denied Axon's petition for inter partes review (IPR) of Digital's 452 Patent, which covers the automatic activation and coordination of multiple recording devices in response to a triggering event such as a law enforcement officer activating the light bar on the vehicle. Not only was the IPR denied, the Patent Office also found that "...the information presented [by Axon] in the Petition does not establish a reasonable likelihood that…

Continue Reading

ThursdayJul 06, 2017 12:48 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on July 6, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ZYXI 19.35% – News: Pays entire remaining loan balance to Triumph Healthcare Finance UCLE 10.04% – News: Receives $722,500 contract with U.S. Air Force to supply portable Tritium air monitors MOMT 5.26% – News: Hosts conference call and webcast for fiscal year 2017 financial results RMGN 5.24% – News: Inks $530,000 contract with an existing customer in the Middle East DRWI 4.20% – News: Posting Q1 fiscal year 2018 results on July 12 KSHB…

Continue Reading

ThursdayJul 06, 2017 12:47 pm

NetworkNewsBreaks – MassRoots, Inc. (MSRT) Shares Rise on Acquisition of Odava Compliance Platform

MassRoots (OTCQB: MSRT) shares are up 8% mid-day on news that the company has entered a definitive agreement to acquire Odava, Inc. for cash and shares of MassRoots’ common stock. Odava is a platform technology company that delivers compliance, point-of-sale, and supply chain management to streamline business operations for the cannabis industry. "We expect with MassRoots' resources and relationships, we can grow the number of dispensaries utilizing Odava from dozens to hundreds by early next year. In the near future, we believe a significant percentage of all transactions occurring in the regulated cannabis industry will occur on our platform," MassRoots…

Continue Reading

ThursdayJul 06, 2017 11:51 am

NetworkNewsBreaks – Catalyst Biosciences, Inc. (NASDAQ: CBIO) Reaches Financial Milestone in Subcutaneous Factor IX Program

Catalyst Biosciences (NASDAQ: CBIO) reports that it has achieved a financial milestone under its collaboration with ISU Abxis following the enrollment of the first patient in its hemophilia B clinical trial. In June 2017, the first patient and cohort were enrolled in a phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B to evaluate Catalyst’s next-generation Factor IX variant, CB 2679d/ISU304, for subcutaneous prophylaxis. ISU Abxis and Catalyst plan to have top-line data from the clinical trial by the end of 2017. “We are pleased to have achieved another financial milestone with the Factor IX clinical program, but…

Continue Reading

ThursdayJul 06, 2017 11:49 am

NetworkNewsBreaks – Cytori Therapeutics, Inc. (NASDAQ: CYTX) Shares Nudge Higher on New Key Cell Therapy Platform Patents

Cytori Therapeutics (NASDAQ: CYTX) this morning said it has received key patents that strengthen its intellectual property portfolio in the U.S. and Europe, sending shares up 2% mid-morning. To date, the company has 107 global patents issued in addition to 45 patent applications pending approval. Many of the most recently issued patents contain claims regarding the use of the company’s Habeo™ Cell Therapy for patients with scleroderma affecting the hands. "Our intellectual property strategy is to continue to strengthen the Cytori Cell Therapy™ platform to help establish and maintain a sustainable competitive advantage. Our main focus is on the primary…

Continue Reading

ThursdayJul 06, 2017 11:46 am

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Names Lead European Principal Investigator in Anticipated Annamycin Clinical Trial

Shares of Moleculin Biotech (NASDAQ: MBRX) are up 11% after the company named Dr. Lidia Gil of Poznan University of Medical Sciences in Poznan, Poland, as the lead European Principal Investigator for the upcoming planned phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML). The trial will commence if the company’s IND is permitted. "Dr. Gill is a dedicated investigator in AML and will bring significant expertise in the area as well as her potential to accelerate enrollment and the completion of our trial," Moleculin's chief medical officer, Dr. Robert Shepard, stated…

Continue Reading

ThursdayJul 06, 2017 10:21 am

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Included in the Horizons Medical Marijuana Life Sciences ETF

ABcann Global Corporation (TSXV: ABCN) yesterday announced its inclusion in the Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ). The ETF is a first-of-its-kind index offering investors direct exposure to a basket of North American life sciences companies with significant business activities in the medical marijuana sector. “The Horizons ETF represents a new type of investment, a fund that tracks an industry in which there is considerable interest but which had no prior investment vehicle through which investors could gain broad exposure,” Aaron Keay, CEO of ABcann, stated in the news release. “Our inclusion in the ETF represents an important…

Continue Reading

WednesdayJul 05, 2017 1:21 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on July 5, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: DCIX 372.29% – News: Settles $148M secured loan facility with RBS with payment of $85M NWGI 35.80% – News: Obtains required certification for betting software platform CERU 32.09% – News: Issues letter to stockholders CLSN 23.27% – News: Completes OVATION study; provides update on immunotherapy trial BLFS 10.43% – News: Reaches agreement to modify existing credit facility SWEE 8.33% – News: Receives GRAS confirmation from independent panel regarding BESTEVIA™ Reb-D MTBC 7.63% – News:…

Continue Reading